Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
Lomustine-temozolomide vs. temozolomide bij glioblastoom met gemethyleerde MGMT-promotor
mrt 2019 | Neuro-oncologie